Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer
Open Access
- 16 May 2017
- journal article
- research article
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 8 (4), 630-638
- https://doi.org/10.1002/jcsm.12180
Abstract
Computed tomography measurements of total skeletal muscle area can detect changes and predict overall survival (OS) in patients with advanced ovarian cancer. This study investigates whether assessment of psoas muscle area reflects total muscle area and can be used to assess sarcopenia in ovarian cancer patients. Ovarian cancer patients (n = 150) treated with induction chemotherapy and interval debulking were enrolled retrospectively in this longitudinal study. Muscle was measured cross sectionally with computed tomography in three ways: (i) software quantification of total skeletal muscle area (SMA); (ii) software quantification of psoas muscle area (PA); and (iii) manual measurement of length and width of the psoas muscle to derive the psoas surface area (PLW). Pearson correlation between the different methods was studied. Patients were divided into two groups based on the extent of change in muscle area, and agreement was measured with kappa coefficients. Cox-regression was used to test predictors for OS. Correlation between SMA and both psoas muscle area measurements was poor (r = 0.52 and 0.39 for PA and PLW, respectively). After categorizing patients into muscle loss or gain, kappa agreement was also poor for all comparisons (all κ < 0.40). In regression analysis, SMA loss was predictive of poor OS (hazard ratio 1.698 (95%CI 1.038–2.778), P = 0.035). No relationship with OS was seen for PA or PLW loss. Change in psoas muscle area is not representative of total muscle area change and should not be used to substitute total skeletal muscle to predict survival in patients with ovarian cancer.Keywords
This publication has 31 references indexed in Scilit:
- Impact of sarcopenia on surgical site infection after restorative proctocolectomy for ulcerative colitisSurgery Today, 2016
- Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patientsJournal of Cachexia, Sarcopenia and Muscle, 2016
- Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian CancerPLOS ONE, 2015
- Sarcopenia Evaluated Using the Skeletal Muscle Index Is a Significant Prognostic Factor for Metastatic Urothelial CarcinomaClinical Genitourinary Cancer, 2015
- Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal CancerPLOS ONE, 2015
- Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess SarcopeniaJournal of Gastrointestinal Surgery, 2015
- Sarcopenia Adversely Impacts Postoperative Complications Following Resection or Transplantation in Patients with Primary Liver TumorsJournal of Gastrointestinal Surgery, 2014
- Pre-operative Assessment of Muscle Mass to Predict Surgical Complications and Prognosis in Patients With Endometrial CancerAnnals of Surgical Oncology, 2014
- Sarcopenia is a prognostic factor in living donor liver transplantationLiver Transplantation, 2013
- Worsening Central Sarcopenia and Increasing Intra‐Abdominal Fat Correlate with Decreased Survival in Patients with Adrenocortical CarcinomaWorld Journal of Surgery, 2012